Chronic low-grade inflammation plays an important role in the pathogenesis of insulin resistance. In the current study, we tested the effects of salsalate, a non-steroidal anti-inflammatory drug, in an animal model of inflammation and metabolic syndrome using spontaneously hypertensive rats (SHR) that transgenically express human C-reactive protein (SHR-CRP rats). We treated 15-month-old male transgenic SHR-CRP rats and nontransgenic SHR with salsalate (200 mg/kg/day) mixed as part of a standard diet for 4 weeks. A corresponding untreated control group of male transgenic SHR-CRP and SHR rats were fed a standard diet without salsalate. In the SHR-CRP transgenic strain, salsalate treatment decreased circulating concentrations of the inflammatory markers TNF-α and MCP-1, reduced oxidative stress in the liver and kidney, increased sensitivity of skeletal muscles to insulin action and improved tolerance to glucose. In SHR controls with no CRP-induced inflammation, salsalate treatment reduced body weight, decreased concentrations of serum free fatty acids and total and HDL cholesterol and increased palmitate oxidation and incorporation in brown adipose tissue. Salsalate regulated inflammation by affecting the expression of genes from MAPK signalling and NOD-like receptor signalling pathways and lipid metabolism by affecting hepatic expression of genes that favour lipid oxidation from PPAR-α signalling pathways. These findings suggest that salsalate has metabolic effects beyond suppressing inflammation.

Centre for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Institute of Molecular Genetics Czech Academy of Sciences Prague Czech Republic

Institute of Physiology Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288: 2709–2716. PubMed

Park YW1, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:.427–436. PubMed PMC

Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132: 2169–2180. doi: 10.1053/j.gastro.2007.03.059 PubMed DOI

Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:.219–246. doi: 10.1146/annurev-physiol-021909-135846 PubMed DOI

Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol. 2010;6: 71–82. doi: 10.1038/nrendo.2009.264 PubMed DOI

Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23: 351–363. doi: 10.1016/j.tem.2012.05.001 PubMed DOI

O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493: 346–355. doi: 10.1038/nature11862 PubMed DOI

Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Exp Opin Investig Drugs. 2015;24: 283–307. PubMed

Wang X, DuBois DC, Cao Y, Jusko WJ, Almon RR. Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment. Diabetes Metab Syndr Obes. 2014;7: 381–389. doi: 10.2147/DMSO.S65818 PubMed DOI PMC

Pravenec M, Kajiya T, Zídek V, Landa V, Mlejnek P, Šimáková M, et al. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension. 2011;57: 731–737. doi: 10.1161/HYPERTENSIONAHA.110.164350 PubMed DOI PMC

Šilhavý J, Zídek V, Landa V, Šimáková M, Mlejnek P, Škop V, et al. Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. Cardiovasc Ther. 2014;32: 59–65. doi: 10.1111/1755-5922.12061 PubMed DOI

Šilhavý J, Zídek V, Mlejnek P, Landa V, Šimáková M, Strnad H, et al. Fumaric acid esters can block pro-inflammatory actions of human CRP and ameliorate metabolic disturbances in transgenic spontaneously hypertensive rats. PLoS One. 2014;9: e101906 doi: 10.1371/journal.pone.0101906 PubMed DOI PMC

Malínská H, Oliyarnyk O, Škop V, Šilhavý J, Landa V, Zídek V, et al. Effects of Metformin on Tissue Oxidative and Dicarbonyl Stress in Transgenic Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein. PLoS One. 2016;11: e0150924 doi: 10.1371/journal.pone.0150924 PubMed DOI PMC

Škop V, Trnovská J, Oliyarnyk O, Marková I, Malínská H, Kazdová L, et al. Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein. Physiol Res. 2016;65: 891–899. PubMed

Gouma E, Simos Y, Verginadis I, Lykoudis E, Evangelou A, Karkabounas S. A simple procedure for estimation of total body surface area and determination of a new value of Meeh's constant in rats. Lab Anim. 2012;46: 40–45. doi: 10.1258/la.2011.011021 PubMed DOI

Liang W, Verschuren L, Mulder P, van der Hoorn JW, Verheij J, van Dam AD, et al. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. Br J Pharmacol. 2015;172: 5293–5305. doi: 10.1111/bph.13315 PubMed DOI PMC

Kuda O, Březinová M, Rombaldová M, Slavíková B, Posta M, et al. Docosahexaenoic acid-derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties. Diabetes. 2016;65: 2580–2590. doi: 10.2337/db16-0385 PubMed DOI

Ward PA, Till GO, Hatherill JR, Annesley TM, Kunkel RG. Systemic complement activation, lung injury, and products of lipid peroxidation. J Clin Invest. 1985;76: 517–527. doi: 10.1172/JCI112001 PubMed DOI PMC

Smyth GK. Limma: linear models for microarray data In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. NewYork: Springer; Pp. 397–420, 2005.

Storey JD (2003) The positive false discovery rate: a Bayesian interpretation and the q-value. Annals Statistics 2003;31: 2013–2035.

Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5: R80 doi: 10.1186/gb-2004-5-10-r80 PubMed DOI PMC

Tarca AL, Draghici S, Khatri P, Hassan S, Mital P, Kim JS, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009;25: 75–82. doi: 10.1093/bioinformatics/btn577 PubMed DOI PMC

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. Series B. 1995;57: 289–300.

Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30: e36 PubMed PMC

van Dam AD, Nahon KJ, Kooijman S, van den Berg SM, Kanhai AA, Kikuchi T, et al. Salsalate activates brown adipose tissue in mice. Diabetes. 2015;64: 1544–1554. doi: 10.2337/db14-1125 PubMed DOI

Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293: 1673–1677. doi: 10.1126/science.1061620 PubMed DOI

Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, et al. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem. 2002;277: 35105–35112. doi: 10.1074/jbc.M201575200 PubMed DOI

Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336: 918–922. doi: 10.1126/science.1215327 PubMed DOI PMC

Smith BK, Ford RJ, Desjardins EM, Green AE, Hughes MC, Houde VP, et al. Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK β1. Diabetes. 2016;65: 3352–3361. doi: 10.2337/db16-0564 PubMed DOI PMC

Pravenec M, Mlejnek P, Zídek V, Landa V, Šimáková M, Šilhavý J, et al. Autocrine effects of transgenic resistin reduce palmitate and glucose oxidation in brown adipose tissue. Physiol Genomics. 2016;48: 420–427. doi: 10.1152/physiolgenomics.00122.2015 PubMed DOI

Mráček T, Cannon B, Houštěk J. IL-1 and LPS but not IL-6 inhibit differentiation and downregulate PPAR gamma in brown adipocytes. Cytokine. 2004;26: 9–15. doi: 10.1016/j.cyto.2003.12.001 PubMed DOI

Wang R, Nelson JC, Wilcox RB. Salsalate and salicylate binding to and their displacement of thyroxine from thyroxine-binding globulin, transthyrin, and albumin. Thyroid. 1999;9: 359–364. doi: 10.1089/thy.1999.9.359 PubMed DOI

Amir S, Robinson B. Thyroidectomy alters the daily pattern of expression of the clock protein, PER2, in the oval nucleus of the bed nucleus of the stria terminalis and central nucleus of the amygdala in rats. Neurosci Lett. 2006;407: 254–257. doi: 10.1016/j.neulet.2006.08.057 PubMed DOI

Carvalho SD, Bianco AC, Silva JE. Effects of hypothyroidism on brown adipose tissue adenylyl cyclase activity. Endocrinology. 1996;137: 5519–5529. doi: 10.1210/endo.137.12.8940379 PubMed DOI

Agrawal NK, Kant S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes. 2014;5: 697–710. doi: 10.4239/wjd.v5.i5.697 PubMed DOI PMC

Maiorino MI, Bellastella G, Giugliano D, Esposito K. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? Endocrine. 2017;55: 360–365. doi: 10.1007/s12020-016-0993-7 PubMed DOI

Goldfine AB, Fonseca V, Jablonski KA, Pyle L, M.A. Staten MA, Shoelson SE. TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152: 346–357. doi: 10.7326/0003-4819-152-6-201003160-00004 PubMed DOI PMC

Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, et al. Targeting inflammation using salsalate in type 2 diabetes study team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013;159: 1–12. doi: 10.7326/0003-4819-159-1-201307020-00003 PubMed DOI PMC

Anderson K, Wherle L, Park M, Nelson K, Nguyen L. Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies. Am Health Drug Benefits. 2014;7: 231–235. PubMed PMC

CD36 regulates substrates utilisation in brown adipose tissue of spontaneously hypertensive rats: In vitro study

Hypolipidemic and insulin sensitizing effects of salsalate beyond suppressing inflammation in a prediabetic rat model

Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress